# Selumetinib for NF2-Related Schwannomatosis

> **NCT07707947** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Beijing Tiantan Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Neurofibromatosis Type 2
- NF2
- NF2-related Schwannomatosis
- Meningioma
- Ependymoma
- Vestibular Schwannoma

## Interventions

- **DRUG:** Selumetinib

## Key facts

- **NCT ID:** NCT07707947
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-15
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07707947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07707947, "Selumetinib for NF2-Related Schwannomatosis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07707947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*